The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

SERPINF2  -  serpin peptidase inhibitor, clade F (alpha...

Homo sapiens

Synonyms: A2AP, AAP, ALPHA-2-PI, API, Alpha-2-AP, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of SERPINF2


Psychiatry related information on SERPINF2

  • The preliminary results were analyzed in terms of the effects of age, sex, smoking, and alcohol consumption on AAP activity in serum [6].
  • Although some of these models have been useful in designing risk reduction programs for API MSM, recent empirical data suggest that the models do not adequately address environmental influences affecting API MSM and limit our choices in prevention strategies to the level of the individual [7].
  • At the present time, a small number of programs are attempting to implement various parts of the CWLA and AAP recommendations for health and mental health services for children in out-of-home care [8].
  • For those children within the PLI group who function at ceiling on language tests, conversational measures may have the potential to signal change, but this finding has not been subjected to group study or to testing in generalized settings [9].
  • AAP releases policy statement on identifying and treating eating disorders [10].

High impact information on SERPINF2


Chemical compound and disease context of SERPINF2


Biological context of SERPINF2


Anatomical context of SERPINF2


Associations of SERPINF2 with chemical compounds


Physical interactions of SERPINF2

  • The plasminogen binding as well as the fibrin binding properties of alpha 2-AP were normal [27].
  • Unlike 125I-Lys-plasmin, the 48-kDa fragment did not form a complex with alpha 2 plasmin inhibitor [28].
  • No evidence of neutrophil migration was observed towards purified complex derived from equine neutrophil elastase and the Spi 1 isoform of equine API, or to crude mixtures of porcine pancreatic elastase and unseparated equine API isoforms, although the same neutrophil preparations actively migrated towards zymosan activated plasma [29].
  • These features of alpha 2-PI and its complex with plasmin are similar to those of plasminogen activator inhibitor type 1 (PAI-1) and its complex with plasminogen activators (PAs), thus they may represent some common features of the SERPINS [30].

Regulatory relationships of SERPINF2


Other interactions of SERPINF2

  • This study has examined the interaction between human leukocyte elastase and alpha 2-plasmin inhibitor, or C1 inactivator, inhibitors of proteases of the complement, kinin, coagulation, and fibrinolytic enzyme systems [21].
  • Similarly, in a purified system composed of plasminogen, fibrinogen and alpha 2-plasmin inhibitor (alpha 2-PI, alpha 2-antiplasmin), such a fibrin clot increased the activity of SAK significantly [31].
  • PLG was significantly decreased 4 and 8 weeks after rhEPO treatment, and ATIII and alpha 2 PI were significantly decreased 8 weeks after rhEPO treatment. alpha 2 PIC was significantly increased 8 weeks after rhEPO treatment, and XL-FDP was significantly increased 4 and 8 weeks after rhEPO treatment [36].
  • The data suggest that alpha 2-PI may originally have inhibited some protease other than plasmin, and protein C may have had an inhibitor different from the present one early in its evolutionary history [37].
  • However, alpha 2-PI and PCI seem to have evolved asynchronously from their substrates [37].

Analytical, diagnostic and therapeutic context of SERPINF2


  1. Organization of the human alpha 2-plasmin inhibitor gene. Hirosawa, S., Nakamura, Y., Miura, O., Sumi, Y., Aoki, N. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  2. Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. Miura, O., Sugahara, Y., Aoki, N. J. Biol. Chem. (1989) [Pubmed]
  3. Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases. Ito, K., Niwa, M., Kawada, T., Tanaka, Y. Tokai J. Exp. Clin. Med. (1986) [Pubmed]
  4. Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. Sakata, Y., Mimuro, J., Aoki, N. Blood (1984) [Pubmed]
  5. The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region. Horrevoets, A.J., Smilde, A.E., Fredenburgh, J.C., Pannekoek, H., Nesheim, M.E. J. Biol. Chem. (1995) [Pubmed]
  6. Alanine aminopeptidase in serum: automated optimized assay, and effects of age, sex, smoking, and alcohol consumption in a selected population. Mueller, P.W., Phillips, D.L., Steinberg, K.K. Clin. Chem. (1987) [Pubmed]
  7. HIV prevention among Asian and Pacific Islander American men who have sex with men: a critical review of theoretical models and directions for future research. Choi, K.H., Yep, G.A., Kumekawa, E. AIDS education and prevention : official publication of the International Society for AIDS Education. (1998) [Pubmed]
  8. The health care needs of children in foster care: a research agenda. Simms, M.D., Halfon, N. Child welfare. (1994) [Pubmed]
  9. Exploring the effects of communication intervention for developmental pragmatic language impairments: a signal-generation study. Adams, C., Lloyd, J., Aldred, C., Baxendale, J. International journal of language & communication disorders / Royal College of Speech & Language Therapists. (2006) [Pubmed]
  10. AAP releases policy statement on identifying and treating eating disorders. Ressel, G.W. American family physician. (2003) [Pubmed]
  11. Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. Miura, O., Hirosawa, S., Kato, A., Aoki, N. J. Clin. Invest. (1989) [Pubmed]
  12. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. Hajjar, K.A., Nachman, R.L. J. Clin. Invest. (1988) [Pubmed]
  13. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. Kluft, C., Nieuwenhuis, H.K., Rijken, D.C., Groeneveld, E., Wijngaards, G., van Berkel, W., Dooijewaard, G., Sixma, J.J. J. Clin. Invest. (1987) [Pubmed]
  14. Alpha-2 antiplasmin in acute nonlymphoblastic leukemia. Cofrancesco, E., Pogliani, E., Salvatore, M., Moreo, G., Boschetti, C., Cortellaro, M. Acta Haematol. (1989) [Pubmed]
  15. Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy. Hayakawa, M., Maki, M. Gynecol. Obstet. Invest. (1988) [Pubmed]
  16. Effect of glycosidase inhibitors on the biosynthesis of alpha 2-plasmin inhibitor and antithrombin III in Hep G2 cells. Mori, K., Wada, Y., Mimuro, J., Matsuda, M., Yoshikuni, Y., Kimura, K., Sakata, Y. Biochim. Biophys. Acta (1994) [Pubmed]
  17. Comparison of Crystal Enteric/Nonfermenter system, API 20E system, and Vitek AutoMicrobic system for identification of gram-negative bacilli. Robinson, A., McCarter, Y.S., Tetreault, J. J. Clin. Microbiol. (1995) [Pubmed]
  18. Prevalence of Escherichia coli O157 in cattle feeds in Midwestern feedlots. Dodd, C.C., Sanderson, M.W., Sargeant, J.M., Nagaraja, T.G., Oberst, R.D., Smith, R.A., Griffin, D.D. Appl. Environ. Microbiol. (2003) [Pubmed]
  19. Inhibitory spectrum of alpha 2-plasmin inhibitor. Saito, H., Goldsmith, G.H., Moroi, M., Aoki, N. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  20. Assignment of the human alpha 2-plasmin inhibitor gene (PLI) to chromosome 17, region pter-p12, by PCR analysis of somatic cell hybrids. Welch, S.K., Francke, U. Genomics (1992) [Pubmed]
  21. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. Brower, M.S., Harpel, P.C. J. Biol. Chem. (1982) [Pubmed]
  22. Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor. Kimura, S., Tamaki, T., Aoki, N. Blood (1985) [Pubmed]
  23. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Weinberg, J.B., Pippen, A.M., Greenberg, C.S. Arthritis Rheum. (1991) [Pubmed]
  24. Congenital deficiency of alpha 2-plasmin inhibitor in three sisters. Yoshioka, A., Kamitsuji, H., Takase, T., Iida, Y., Tsukada, S., Mikami, S., Fukui, H. Haemostasis (1982) [Pubmed]
  25. Vitamin E, pulmonary functions, and phagocyte-mediated oxidative stress in smokers and nonsmokers. van Antwerpen, V.L., Theron, A.J., Richards, G.A., Steenkamp, K.J., van der Merwe, C.A., van der Walt, R., Anderson, R. Free Radic. Biol. Med. (1995) [Pubmed]
  26. Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitor. Petersen, L.C., Clemmensen, I. Biochem. J. (1981) [Pubmed]
  27. Mild haemostatic problems associated with congenital heterozygous alpha 2-antiplasmin deficiency. Leebeek, F.W., Stibbe, J., Knot, E.A., Kluft, C., Gomes, M.J., Beudeker, M. Thromb. Haemost. (1988) [Pubmed]
  28. Regulation of macrophage receptor-bound plasmin by autoproteolysis. Falcone, D.J., Borth, W., McCaffrey, T.A., Mathew, J., McAdam, K. J. Biol. Chem. (1994) [Pubmed]
  29. Neutrophil chemotaxis in the horse is not mediated by a complex of equine neutrophil elastase and equine alpha-1-proteinase inhibitor. Scudamore, C.L., Pemberton, A., Watson, E.D., Miller, H.R. Br. Vet. J. (1993) [Pubmed]
  30. Dissociation of alpha 2-plasmin-inhibitor-plasmin complex and regeneration of plasmin activity by SDS treatment. Yan, D., Urano, T., Takada, Y., Takada, A. Thromb. Res. (1993) [Pubmed]
  31. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor. Sakai, M., Watanuki, M., Matsuo, O. Biochem. Biophys. Res. Commun. (1989) [Pubmed]
  32. Binding site of alpha 2-plasmin inhibitor to plasminogen. Sugiyama, N., Sasaki, T., Iwamoto, M., Abiko, Y. Biochim. Biophys. Acta (1988) [Pubmed]
  33. The fusion of IGF I with stromal cell-derived factor I or alpha1 proteinase inhibitor alters their mitogenic or chemotactic activities while keeping their ability to inhibit HIV-1-gp120 binding. Sandoval, C., Stojanova, A., DiFalco, M.R., Congote, L.F. Biochem. Pharmacol. (2003) [Pubmed]
  34. Lipoprotein (a) regulates plasmin generation and inhibition. Edelberg, J., Pizzo, S.V. Chem. Phys. Lipids (1994) [Pubmed]
  35. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. Tamaki, T., Aoki, N. J. Biol. Chem. (1982) [Pubmed]
  36. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis. Tomura, S., Nakamura, Y., Tachibana, K., Deguchi, F., Ando, R., Chida, Y., Marumo, F. Blood Purif. (1993) [Pubmed]
  37. Structure of human alpha 2-plasmin inhibitor deduced from the cDNA sequence. Tone, M., Kikuno, R., Kume-Iwaki, A., Hashimoto-Gotoh, T. J. Biochem. (1987) [Pubmed]
  38. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot. Takada, A., Ito, T., Takada, Y. Thromb. Haemost. (1980) [Pubmed]
  39. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis. Páramo, J.A., Alfaro, M.J., Rocha, E. Thromb. Haemost. (1985) [Pubmed]
  40. Effects of minimal-dose aprotinin on coronary artery bypass grafting. Hayashida, N., Isomura, T., Sato, T., Maruyama, H., Kosuga, K., Aoyagi, S. J. Thorac. Cardiovasc. Surg. (1997) [Pubmed]
WikiGenes - Universities